Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Fujino H, Tanaka M, Imamura M, Morio K, Ono A, Nakahara T, Murakami E, Kawaoka T, Takahashi S, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K.

BMC Gastroenterol. 2019 Oct 24;19(1):169. doi: 10.1186/s12876-019-1092-z.

2.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.

Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K.

J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602. [Epub ahead of print]

PMID:
31584207
3.

Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Namba M, Hiramatsu A, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Chayama K.

J Gastroenterol. 2019 Sep 4. doi: 10.1007/s00535-019-01623-4. [Epub ahead of print]

PMID:
31485782
4.

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Ohya K, Imamura M, Osawa M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Hiramatsu A, Tsuge M, Aikata H, Hayes CN, Chayama K.

Clin J Gastroenterol. 2019 Aug 28. doi: 10.1007/s12328-019-01039-w. [Epub ahead of print]

PMID:
31463795
5.

Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy.

Ohya K, Kawaoka T, Namba M, Uchikawa S, Kodama K, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Yamauchi M, Imamura M, Chayama K, Aikata H.

Sci Rep. 2019 Aug 20;9(1):12101. doi: 10.1038/s41598-019-48045-z.

6.

Infrared spectrum of hydrogenated corannulene rim-HC20H10 isolated in solid para-hydrogen.

Sundararajan P, Tsuge M, Baba M, Sakurai H, Lee YP.

J Chem Phys. 2019 Jul 28;151(4):044304. doi: 10.1063/1.5111169.

PMID:
31370543
7.

Effect of L-Leucine Therapy on Hematopoietic Function in Elderly Myelodysplastic Syndrome Patients.

Ito K, Hayashi T, Inaguma Y, Terazawa T, Ando M, Ando Y, Tsuge M, Kato A, Shimato A, Suzuki S, Kato S, Tomita A, Yamada S, Emi N.

Biol Pharm Bull. 2019 Oct 1;42(10):1651-1657. doi: 10.1248/bpb.b19-00184. Epub 2019 Jul 25.

8.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

PMID:
31199224
9.

Regulation of the Hepatitis B virus replication and gene expression by the multi-functional protein TARDBP.

Makokha GN, Abe-Chayama H, Chowdhury S, Hayes CN, Tsuge M, Yoshima T, Ishida Y, Zhang Y, Uchida T, Tateno C, Akiyama R, Chayama K.

Sci Rep. 2019 Jun 11;9(1):8462. doi: 10.1038/s41598-019-44934-5.

10.

Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection.

Tsuge M, Uchida T, Walsh K, Ishida Y, Tateno C, Kumar U, Glenn JS, Koh C, Heller T, Uprichard SL, Dahari H, Chayama K.

Viruses. 2019 Mar 15;11(3). pii: E263. doi: 10.3390/v11030263.

11.

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis.

Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, Tanaka J, Chayama K.

Hepatol Commun. 2019 Jan 22;3(3):348-355. doi: 10.1002/hep4.1309. eCollection 2019 Mar.

12.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.

Tsushima K, Tsuge M, Hiraga N, Uchida T, Murakami E, Makokha GN, Kurihara M, Nomura M, Hiyama Y, Fujino H, Ono A, Nakahara T, Yamauchi M, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Aikata H, Hayes CN, Chayama K.

J Gastroenterol. 2019 Jul;54(7):650-659. doi: 10.1007/s00535-019-01558-w. Epub 2019 Feb 21.

PMID:
30790056
13.

Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.

Namba M, Kawaoka T, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Baba Y, Awai K, Chayama K.

Clin J Gastroenterol. 2019 Aug;12(4):341-346. doi: 10.1007/s12328-019-00938-2. Epub 2019 Jan 31.

PMID:
30706429
14.

Correction: Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2019;23(8):709. doi: 10.3851/IMP3289. No abstract available.

PMID:
30632982
15.

Early experience of seven hepatocellular carcinoma cases treated with regorafenib.

Uchikawa S, Kawaoka T, Aikata H, Kodama K, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K.

Clin Case Rep. 2018 Oct 11;6(11):2217-2223. doi: 10.1002/ccr3.1791. eCollection 2018 Nov.

16.

Prospective Cohort Study of Congenital Cytomegalovirus Infection during Pregnancy with Fetal Growth Restriction: Serologic Analysis and Placental Pathology.

Tsuge M, Hida AI, Minematsu T, Honda N, Oshiro Y, Yokoyama M, Kondo Y.

J Pediatr. 2019 Mar;206:42-48.e2. doi: 10.1016/j.jpeds.2018.10.003. Epub 2018 Nov 6.

PMID:
30413316
17.

The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.

Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H.

J Med Virol. 2019 Apr;91(4):650-658. doi: 10.1002/jmv.25352. Epub 2018 Nov 19.

PMID:
30381831
18.

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.

Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group.

J Gastroenterol. 2019 Mar;54(3):291-296. doi: 10.1007/s00535-018-1520-9. Epub 2018 Oct 17.

PMID:
30334096
19.

Activation of Molecular Hydrogen by Arylcarbenes.

Mendez-Vega E, Maehara M, Raut AH, Mieres-Perez J, Tsuge M, Lee YP, Sander W.

Chemistry. 2018 Dec 12;24(70):18801-18808. doi: 10.1002/chem.201804657. Epub 2018 Nov 19.

PMID:
30312518
20.

Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes.

Tsuge M, Hiraga N, Zhang Y, Yamashita M, Sato O, Oka N, Shiraishi K, Izaki Y, Makokha GN, Uchida T, Kurihara M, Nomura M, Tsushima K, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Imamura M, Kawakami Y, Aikata H, Ochi H, Hayes CN, Fujita T, Chayama K.

Virology. 2018 Dec;525:48-61. doi: 10.1016/j.virol.2018.08.020. Epub 2018 Sep 18.

PMID:
30240958
21.

Spirituality, Religiosity, Quality of Life and Mental Health Among Pantaneiros: A Study Involving a Vulnerable Population in Pantanal Wetlands, Brazil.

Gonçalves LM, Tsuge MLT, Borghi VS, Miranda FP, Sales APA, Lucchetti ALG, Lucchetti G.

J Relig Health. 2018 Dec;57(6):2431-2443. doi: 10.1007/s10943-018-0681-4.

PMID:
30066264
22.

Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma.

Kawaoka T, Aikata H, Kobayashi T, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Baba Y, Awai K, Chayama K.

Hepatol Res. 2018 Dec;48(13):1118-1130. doi: 10.1111/hepr.13232. Epub 2018 Aug 23.

PMID:
30030881
23.

Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.

Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group.

J Med Virol. 2018 Dec;90(12):1834-1840. doi: 10.1002/jmv.25267. Epub 2018 Aug 13.

PMID:
30016555
24.

CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients.

Nomura M, Tsuge M, Uchida T, Hiraga N, Kurihara M, Tsushima K, Fujino H, Nakahara T, Murakami E, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Tanaka S, Chayama K.

J Viral Hepat. 2018 Dec;25(12):1555-1564. doi: 10.1111/jvh.12970. Epub 2018 Aug 29.

PMID:
29998562
25.

Infrared spectra of 3-hydroxy-(1H)-pyridinium cation and 3-hydroxy-(1H)-pyridinyl radical isolated in solid para-hydrogen.

Tsuge M, Lai CP, Lee YP.

J Chem Phys. 2018 Jul 7;149(1):014306. doi: 10.1063/1.5038363.

PMID:
29981551
26.

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.

Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2018 Aug;99(8):1058-1065. doi: 10.1099/jgv.0.001091. Epub 2018 Jun 19.

PMID:
29916799
27.

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.

Hatooka M, Kawaoka T, Aikata H, Inagaki Y, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Awai K, Masaki K, Waki K, Kohno H, Kohno H, Moriya T, Nagaoki Y, Tamura T, Amano H, Katamura Y, Chayama K.

BMC Cancer. 2018 Jun 4;18(1):633. doi: 10.1186/s12885-018-4519-y.

28.

Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study.

Tatsukawa Y, Tsuge M, Kawakami Y, Hiyama Y, Murakami E, Kurihara M, Nomura M, Tsushima K, Uchida T, Nakahara T, Miki D, Kawaoka T, Abe-Chayama H, Imamura M, Aikata H, Ochi H, Hayes CN, Kawakami H, Chayama K.

Antivir Ther. 2018;23(8):639-646. doi: 10.3851/IMP3240. Erratum in: Antivir Ther. 2019;23(8):709.

PMID:
29856363
29.

Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice.

Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K.

Hepatol Res. 2018 Sep;48(10):814-820. doi: 10.1111/hepr.13180. Epub 2018 May 27.

PMID:
29682855
30.

Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.

Kodama K, Kawaoka T, Aikata H, Uchikawa S, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K.

J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.

PMID:
29645345
31.

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.

Teraoka Y, Uchida T, Imamura M, Osawa M, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K; Hiroshima Liver Study Group.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157. doi: 10.1016/j.bbrc.2018.04.005. Epub 2018 Apr 13.

PMID:
29621544
32.

Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring.

Honda F, Hiramatsu A, Hyogo H, Aikata H, Daijo K, Teraoka Y, Inagaki Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Yoneda M, Tsuge M, Imamura M, Kawakami Y, Ochi H, Chayama K.

PLoS One. 2018 Apr 3;13(4):e0195028. doi: 10.1371/journal.pone.0195028. eCollection 2018.

33.

SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma.

Tsuge M, Osaki M, Sasaki R, Hirahata M, Okada F.

Int J Mol Sci. 2018 Mar 5;19(3). pii: E736. doi: 10.3390/ijms19030736.

34.

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.

Kodama K, Kawaoka T, Aikata H, Uchikawa S, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Masaki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Kimura T, Nagata Y, Chayama K.

Oncology. 2018;94(4):215-222. doi: 10.1159/000486483. Epub 2018 Feb 9.

PMID:
29428943
35.

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis.

Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio K, Fujino H, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K.

Hepatol Res. 2018 Mar;48(4):264-274. doi: 10.1111/hepr.12996. Epub 2017 Dec 11.

PMID:
29114970
36.

Spectroscopy of prospective interstellar ions and radicals isolated in para-hydrogen matrices.

Tsuge M, Tseng CY, Lee YP.

Phys Chem Chem Phys. 2018 Feb 21;20(8):5344-5358. doi: 10.1039/c7cp05680j.

PMID:
28967028
37.

The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients.

Kurihara M, Tsuge M, Murakami E, Mori N, Ohishi W, Uchida T, Fujino H, Nakahara T, Abe-Chayama H, Kawaoka T, Miki D, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Zhang Y, Makokha GN, Hayes CN, Chayama K.

Antivir Ther. 2018;23(3):239-248. doi: 10.3851/IMP3196.

PMID:
28933704
38.

Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study.

Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K, Takaki S, Mori N, Honda Y, Arataki K, Takahashi S, Kira S, Tamura T, Masuda K, Nakamura T, Kikkawa M, Chayama K.

J Gastroenterol. 2018 Apr;53(4):548-556. doi: 10.1007/s00535-017-1380-8. Epub 2017 Aug 16.

PMID:
28815329
39.

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K.

PLoS One. 2017 Aug 10;12(8):e0182710. doi: 10.1371/journal.pone.0182710. eCollection 2017.

40.

Infrared spectra and anharmonic coupling of proton-bound nitrogen dimers N2-H+-N2, N2-D+-N2, and 15N2-H+-15N2 in solid para-hydrogen.

Liao HY, Tsuge M, Tan JA, Kuo JL, Lee YP.

Phys Chem Chem Phys. 2017 Aug 9;19(31):20484-20492. doi: 10.1039/c7cp03847j.

PMID:
28752865
41.

Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.

Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, Tsuge M, Hiraga N, Hayes CN, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Abe-Chayama H, Furusho H, Shintani T, Kurihara H, Miyauchi M, Takata T, Arihiro K, Chayama K.

J Gastroenterol. 2018 Feb;53(2):269-280. doi: 10.1007/s00535-017-1368-4. Epub 2017 Jul 24.

PMID:
28741270
42.

Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00725-17. doi: 10.1128/AAC.00725-17. Print 2017 Sep.

43.

Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.

Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Aikata H, Hayes CN, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K.

J Med Virol. 2017 Nov;89(11):1963-1972. doi: 10.1002/jmv.24885. Epub 2017 Jul 25.

PMID:
28657143
44.

Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E.

J Gastroenterol. 2018 Feb;53(2):247-257. doi: 10.1007/s00535-017-1360-z. Epub 2017 Jun 20.

PMID:
28634723
45.

Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia.

Daijo K, Kawaoka T, Nakahara T, Nagaoki Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Hara K, Tajima G, Kobayashi M, Chayama K.

Clin J Gastroenterol. 2017 Aug;10(4):383-387. doi: 10.1007/s12328-017-0753-0. Epub 2017 Jun 9.

PMID:
28597413
46.

Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.

Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K.

J Gastroenterol. 2018 Jan;53(1):161-162. doi: 10.1007/s00535-017-1352-z. No abstract available.

PMID:
28555325
47.

Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma.

Teraoka Y, Kimura T, Aikata H, Daijo K, Osawa M, Honda F, Nakamura Y, Morio K, Morio R, Hatooka M, Kobayashi T, Nakahara T, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Nagata Y, Chayama K.

Hepatol Res. 2018 Feb;48(2):193-204. doi: 10.1111/hepr.12916. Epub 2017 Jun 24.

PMID:
28544062
48.

Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury.

Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, Kobayashi T, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Nelson Hayes C, Tsugawa K, Yokozaki M, Chayama K.

J Gastroenterol. 2017 Dec;52(12):1252-1257. doi: 10.1007/s00535-017-1345-y. Epub 2017 May 5.

PMID:
28477171
49.

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.

Masuda K, Ono A, Aikata H, Kawaoka T, Nelson Hayes C, Teraoka Y, Daijo K, Nakamura-Inagaki Y, Morio K, Fujino H, Kan H, Uchida T, Masaki K, Kobayashi T, Nakahara T, Makokha GN, Zhang Y, Nagaoki Y, Miki D, Tsuge M, Hiramatsu A, Imamura M, Abe-Chayama H, Kawakami Y, Ochi H, Chayama K.

J Gastroenterol. 2018 Jan;53(1):107-118. doi: 10.1007/s00535-017-1348-8. Epub 2017 May 4. Erratum in: J Gastroenterol. 2017 May 29;:.

PMID:
28474222
50.

Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.

Tsuge M, Uchida T, Hiraga N, Kan H, Makokha GN, Abe-Chayama H, Miki D, Imamura M, Ochi H, Hayes CN, Shimozono R, Iwamura T, Narumi H, Suzuki T, Kainoh M, Taniguchi T, Chayama K.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00183-17. doi: 10.1128/AAC.00183-17. Print 2017 Jun.

Supplemental Content

Support Center